Open AccessRace, Ethnicity, and Clinical Outcomes in Hormone Receptor-Positive, HER2-Negative, Node-Negative Breast Cancer in the Randomized TAILORx Trial
Author(s) -
Kathy S. Albain,
Robert J. Gray,
Della Makower,
Amir Faghih,
Daniel F. Hayes,
Charles E. Geyer,
Elizabeth Claire Dees,
Matthew P. Goetz,
John A. Olson,
T. Lively,
Sunil Badve,
Tom Saphner,
Lynne I. Wagner,
Timothy J. Whelan,
Matthew J. Ellis,
William C. Wood,
Maccon M. Keane,
Henry Gómez,
Pavan S. Reddy,
Timothy F. Goggins,
Ingrid A. Mayer,
Adam Brufsky,
Deborah Toppmeyer,
Virginia Kaklamani,
Jeffrey L. Berenberg,
Jeffrey S. Abrams,
George W. Sledge,
Joseph A. Sparano
Publication year - 2020
Publication title -
journal of the national cancer institute
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.797
H-Index - 356
eISSN - 1460-2105
pISSN - 0027-8874
DOI - 10.1093/jnci/djaa148
Subject(s) - medicine , hazard ratio , breast cancer , ethnic group , oncology , confidence interval , population , cancer , hormone therapy , randomized controlled trial , demography , environmental health , sociology , anthropology
Black race is associated with worse outcomes in early breast cancer. We evaluated clinicopathologic characteristics, the 21-gene recurrence score (RS), treatment delivered, and clinical outcomes by race and ethnicity among women who participated in the Trial Assigning Individualized Options for Treatment.